Navigation Links
Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission
Date:7/30/2014

of Regeneron to manufacture and manage supply chains for multiple products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare LLC, to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2013 and its Form 10-Q for the quarter ended March 31, 2014.  The reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise. Contacts Sanofi:Media Relations

Investor Relations Jack Cox

Sebastien MartelTel: +33 (0) 1 53 77 94 74

Tel: +33 (0)1 53 77 45 45Mobile: +33 (0) 6 78 52 05 36

E-mail: IR@sanofi.com E-mail: Jack.Cox@sanofi.com <
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014
2. Regenerons Chief Executive Officer and Chief Scientific Officer named "Management Team of the Year" by Scrip Intelligence
3. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
4. After 18 Months On the U.S. Market, Regenerons Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
5. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
6. Regeneron Reports First Quarter 2013 Financial and Operating Results
7. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
8. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
9. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
10. Regeneron Announces March 2012 Investor Conference Presentations
11. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... Nasa Ames Research Base, Mountain View, CA (PRWEB) September ... announces the launch of its fundraising campaign on Indiegogo. ... producer Matt Rutherford, features Stephen Hawking, Buzz Aldrin, Shimon ... , Exponential technology is changing the world and there’s ... students how to harness it to help change the ...
(Date:9/11/2014)... it has uncovered the secret behind the unusual ... metal dichalcogenide (TMDC) materials, the two-dimensional semiconductors that ... , Using two-photon excitation spectroscopy, the researchers ... most promising of 2D materials, and found evidence ... energy states in which single photons can be ...
(Date:9/11/2014)... SARASOTA, Fla. , Sept. 11, 2014 ... novel anti-infective pharmaceuticals, announced today that the ... issued a ,Notice of Allowance, for patent ... Their Uses,.  The ,486 patent application relates ... act through gene-silencing and can be designed ...
(Date:9/11/2014)... TORONTO , Sept. 11, 2014 /PRNewswire/ - Portage ... Canadian Securities Exchange: PBT.U), announces that it intends ... to US$ 2 million for funding its preclinical ... Holding Company Limited, ("Biohaven"). The Company ... up to 20 million common shares at a ...
Breaking Biology Technology:Documentary Film that Follows Singularity University Students as They Change the World Launches its IndieGoGo Fundraising Campaign 2Excitonic dark states shed light on TMDC atomic layers 2Excitonic dark states shed light on TMDC atomic layers 3Lakewood-Amedex Receives Notice Of Allowance From The United States Patent and Trademark Office (USPTO) For A New Patent Covering Its nanoRNA Gene-Silencing Technology 2Lakewood-Amedex Receives Notice Of Allowance From The United States Patent and Trademark Office (USPTO) For A New Patent Covering Its nanoRNA Gene-Silencing Technology 3Portage Announces Proposed Private Placement 2Portage Announces Proposed Private Placement 3Portage Announces Proposed Private Placement 4
... increase their risk of developing diabetes, a study suggests. ... a resistance to insulin, the hormone that controls blood sugar ... how low testosterone levels in fat tissue can be instrumental ... present throughout the body. Low testosterone levels are linked to ...
... RICHLAND, Wash. Creators of a nanotech-based system that ... submarine, while providing a more environmentally friendly removal process, ... for 2012. The technology Self Assembled Monolayers on ... into future submarines to improve air quality for sailors ...
... a naturally occurring asphalt first appeared on roads in about ... the ancient city of Babylon. Under the onslaught of ... for anywhere near 2,700 years. But at Michigan Technological University, ... to fight off cracks, rutting and potholes. One of ...
Cached Biology Technology:Low testosterone levels could raise diabetes risk for men 2Clearing the air: PNNL technology wins award for improving submarine air quality 2Using nanoclays to build better asphalt pavement 2
(Date:9/11/2014)... Amsterdam, NL, 11 September 2014 Patients with ... preparation and ingestion, which could contribute to poor ... Published studies have also suggested that PD is ... control groups. A report published in the ... in patients with mild-to-moderate PD, finding that the ...
(Date:9/11/2014)... South San Francisco, Calif., Sept. 11, 2014 UT ... a new collaboration to advance research and drug development ... of nerve cells. , This week, UT Southwestern researchers ... P7C3 compounds, a class that has been shown to ... previously licensed the P7C3 compounds to Dallas-based 2M Companies. ...
(Date:9/11/2014)... of oil that reached the Gulf of Mexico shore in ... first time such an estimate was reported, and the study ... and Technology . , The researchers found that 22,000 ... finding will help officials determine the persistence of oil on ... The study was conducted by the Center for Natural Resources ...
Breaking Biology News(10 mins):Few mild-to-moderate Parkinson's disease patients suffer from malnutrition, yet almost one-third are at risk 2Calico enters into exclusive collaboration with 2M to develop UTSW technology 2Calico enters into exclusive collaboration with 2M to develop UTSW technology 3NJIT researchers working to safeguard the shoreline 2
... , July 29, 2013 /PRNewswire-iReach/ -- In the current ... data. The bigger challenge is using data to make ... of Big Data, the must-attend big data event of ... Quality Research for Kaiser Permanente, will share his experience ...
... DALLAS July 29, 2013 A seafood contaminant ... like a spy to infiltrate cells and quickly open ... Southwestern Medical Center report. Vibrio parahaemolyticus ... host cells. One of those effectors, VopQ, almost immediately ...
... that beginning in January 2014 it will be publishing ... Institute of Biological Sciences (AIBS). Since 1964, ... overviews of current research in biology, accompanied by essays ... the conceptual underpinnings of the biological sciences., A peer-reviewed, ...
Cached Biology News:Kaiser Permanente's Robert Mangel to Speak at Rock Stars of Big Data: Register Now to Reserve Your Space 2Kaiser Permanente's Robert Mangel to Speak at Rock Stars of Big Data: Register Now to Reserve Your Space 3UT Southwestern researchers identify novel mechanism that helps stomach bug cause illness 2Oxford University Press to publish BioScience journal from 2014 2
... the MSn performance of the LTQ linear ... generate extensive structural information for the most ... Multiple dissociation techniques (PQD, ETD, CID) , ... , Fast polarity switching for high-sensitivity analysis ...
Request Info...
The Synergy HT utilizes a unique dual-optics design combined with monochromator wavelength selection to provide uncompromised performance in absorbance, fluorescence and luminescence reading modes. ...
... SYBR Green I nucleic acid gel stain ... that has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... acid stain has also found uses in capillary ...
Biology Products: